Media coverage about Biohaven Pharmaceutical (NYSE:BHVN) has trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Biohaven Pharmaceutical earned a news impact score of 0.16 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.3809435758945 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s scoring:
NYSE:BHVN traded down $0.12 on Monday, hitting $26.50. The company’s stock had a trading volume of 23,170 shares, compared to its average volume of 751,852. The firm has a market capitalization of $958.79 and a price-to-earnings ratio of -5.36. Biohaven Pharmaceutical has a one year low of $16.50 and a one year high of $39.51.
Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Tuesday, March 6th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.58. equities research analysts forecast that Biohaven Pharmaceutical will post -4.27 earnings per share for the current fiscal year.
BHVN has been the subject of several research reports. Zacks Investment Research cut Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Canaccord Genuity reissued a “buy” rating and issued a $39.00 target price (up from $30.00) on shares of Biohaven Pharmaceutical in a research note on Thursday, February 22nd. Needham & Company LLC restated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. Piper Jaffray restated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Monday, March 26th. Finally, Barclays lowered Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $30.00 to $25.00 in a report on Thursday, April 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Biohaven Pharmaceutical presently has an average rating of “Buy” and an average target price of $37.14.
In related news, Director Gregory Bailey sold 50,000 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $33.71, for a total transaction of $1,685,500.00. Following the sale, the director now owns 2,516,701 shares of the company’s stock, valued at $84,837,990.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Declan Doogan sold 128,058 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $26.95, for a total value of $3,451,163.10. Following the sale, the director now directly owns 2,583,289 shares in the company, valued at approximately $69,619,638.55. The disclosure for this sale can be found here. Insiders sold 427,715 shares of company stock worth $12,410,151 in the last ninety days. 34.20% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/16/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-biohaven-pharmaceutical-bhvn-share-price.html.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.